-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

New Gene Editing Technologies

Program: Scientific Program
Session: JOINT SESSION: Therapeutic Gene Editing of Stem Cells in Classical and Malignant Hematology
Hematology Disease Topics & Pathways:
Research, Translational Research
Sunday, December 8, 2024, 9:30 AM-11:05 AM

Justin Eyquem, PhD

University of California San Francisco, San Fransisco, CA; Department of Medicine, University of California San Francisco, San Francisco, CA; Parker Institute for Cancer Immunotherapy, San Francisco, CA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA

Disclosures: Eyquem: Takeda: Patents & Royalties, Research Funding; Treefrog Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Enterome: Consultancy, Membership on an entity's Board of Directors or advisory committees; Fate Therapeutics: Patents & Royalties; Atara Bio: Patents & Royalties; Minerva bio: Patents & Royalties; Mnemo Therapeutics: Consultancy, Current equity holder in private company, Patents & Royalties, Research Funding.

See more of: JOINT SESSION: Therapeutic Gene Editing of Stem Cells in Classical and Malignant Hematology
See more of: Scientific Program
Previous Presentation | Next Presentation >>